Premenstrual dysphoric disorder
Methodology & AI Transparency ⓘ
Premenstrual dysphoric disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Premenstrual dysphoric disorder is an ICD-10-CM indexed diagnosis (F32.81) within Depression, Bipolar & Mood Disorders.
- 2 Real-world patient consensus: Federal ICD-10-CM code F32.81 categorizes Premenstrual dysphoric disorder under Depression, Bipolar & Mood Disorders.
- 3 Typical cash cost range: Differential triage of Premenstrual dysphoric disorder (F32.81) utilizes sleep-wake rhythm assessment [Premenstrual dysphoric disorder F32.81].
- 4 Top reported side effects / signs: Longitudinal Premenstrual dysphoric disorder monitoring tracks PHQ-9 Symptom Severity in Premenstrual dysphoric disorder (F32.81: Score) toward < 4 (clinical remission) (F32.81).
Ask our AI Specialists anything about Premenstrual dysphoric disorder
What Is Premenstrual dysphoric disorder?
Premenstrual dysphoric disorder is an ICD-10-CM indexed diagnosis (F32.81) within Depression, Bipolar & Mood Disorders. Clinical evaluation centers on sleep-wake rhythm assessment [Premenstrual dysphoric disorder F32.81] alongside serial PHQ-9 Symptom Severity in Premenstrual dysphoric disorder (F32.81: Score) tracking (< 4 (clinical remission) (F32.81)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
In Premenstrual dysphoric disorder (F32.81), physiological disruption stems from prefrontal-limbic circuit dysregulation [Premenstrual dysphoric disorder F32.81], informing Depression, Bipolar & Mood Disorders protocols that track TSH & Free in Premenstrual dysphoric disorder (F32.81: T4 Rule-Out) (TSH 0.8 – 2.5 mIU/L (F32.81)).
Common Symptoms & Clinical Signs
- • Presentation of Premenstrual dysphoric disorder (F32.81): loss of interest in Premenstrual dysphoric disorder (F32.81: or pleasure in)
- • Secondary Premenstrual dysphoric disorder clinical sign: persistent low mood, in Premenstrual dysphoric disorder (F32.81: emotional flatness, or)
- • Symptom flares in Premenstrual dysphoric disorder correlating with PHQ-9 Symptom Severity in Premenstrual dysphoric disorder (F32.81: Score) deviation outside < 4 (clinical remission) (F32.81)
- • Functional depression & mood impact requiring sleep-wake rhythm assessment [Premenstrual dysphoric disorder F32.81] evaluation (F32.81)
Premenstrual dysphoric disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F32.81 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Premenstrual dysphoric disorder (F32.81: Score) | < 4 (clinical remission) (F32.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Premenstrual dysphoric disorder (F32.81: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F32.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Premenstrual dysphoric disorder (F32.81: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F32.81) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Premenstrual dysphoric disorder
Treatment selection for Premenstrual dysphoric disorder depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Premenstrual dysphoric disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in: What a 310-Participant Study Found Conclusions: Patients with TRD without a demonstrated response within the first week of treatment may still derive benefit from a full 4-week induction course of esketamine nasal spray. The Journal of clinical psychiatry • 2021-07-20 • Phase III Randomized Trial | N = 310 | 93/100 | PMID 34288609 ↗ |
| New Insights on Dorsolateral Prefrontal Cortex and Subcallosal Cingulate Connectivity Show: What a 279-Participant Study Found The level of functional connectivity seeded in both the DLPFC and the subcallosal cingulate cortex networks may play an important role in identifying a favorable response to sertraline over placebo. Biological psychiatry. Cognitive neuroscience and neuroimaging • 2021-01-15 • Randomized Controlled Trial | N = 279 | 93/100 | PMID 32921587 ↗ |
| Can This Approach Help? Inside the Latest Research on Cariprazine on reducing symptoms of irritability, hostility, and agitation in Cariprazine demonstrated specific antihostility/irritability and anti-agitation effects in patients with manic/mixed episodes of bipolar I disorder and baseline hostility, irritability, or agitation. Journal of affective disorders • 2024-08-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38657773 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of pentoxifylline combination therapy in depression: a However, the full symptom relief rate, time to full symptom relief and time to treatment response did not show any significant difference between trial groups. International clinical psychopharmacology • 2021-05-01 • Randomized Controlled Trial | N = 56 | 88/100 | PMID 33724254 ↗ |
| Can This Approach Help? Inside the Latest Research on Short-term dynamic psychotherapy versus pharmacotherapy for depression: a This trial of urban MDD patients failed to confirm that either active treatment was better than placebo. The Journal of clinical psychiatry • 2012-01-15 • Randomized Controlled Trial | N = 156 | 88/100 | PMID 22152401 ↗ |
Premenstrual dysphoric disorder Patient Community & “People Like Me” Threads
Filter Premenstrual dysphoric disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.